Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 and Binimetinib in Solid Tumors With RAS Pathway Alterations and TNBC
NCT05111561Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZEN3694 in solid tumor and triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Primary endpoints: Incidence of dose limiting toxicities at 28 days and Incidence of Adverse Events. Started Aug 2022; status: recruiting.
02
Drugs
ZEN3694
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05111561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111561.